Asset Details
Do you wish to reserve the book?
Efficiency of whole-body positron emission tomography/computed tomography using .sup.18F-Fluorodeoxyglucose in detecting the cause of elevated cancer antigen 125 serum level in treated ovarian cancer patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Efficiency of whole-body positron emission tomography/computed tomography using .sup.18F-Fluorodeoxyglucose in detecting the cause of elevated cancer antigen 125 serum level in treated ovarian cancer patients
Do you wish to request the book?
Efficiency of whole-body positron emission tomography/computed tomography using .sup.18F-Fluorodeoxyglucose in detecting the cause of elevated cancer antigen 125 serum level in treated ovarian cancer patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Efficiency of whole-body positron emission tomography/computed tomography using .sup.18F-Fluorodeoxyglucose in detecting the cause of elevated cancer antigen 125 serum level in treated ovarian cancer patients
2023
Overview
Ovarian cancer is one of the leading causes of death in females worldwide. Early diagnosis and accurate staging are mandatory for proper management. Anatomic imaging and serum cancer antigen 125 (CA 125) measurement have been widely used for follow up of treated ovarian cancer patients to detect residual or recurrent neoplasia. The aim of this study was to assess the value of whole-body positron emission tomography/computed tomography using .sup.18F-Fluorodeoxyglucose (.sup.18F-FDG PET/CT) in follow up of ovarian cancer patients presented with elevated CA 125 serum level. The current study was performed over a period of 2 years between March 2019 and March 2022. Seventy-six patients were included with history of treated ovarian cancer (underwent either surgical resection and/or received radio/chemotherapy) but were subsequently presented rising tumor marker CA-125 serum level (more than 35 U/ml). All patients underwent a .sup.18F-FDG PET/CT scanning on whole body. The FDG-PET results were correlated with histological findings, radiological or tumor marker/clinical follow-up. The patients with inconsistent findings were followed up with U/S, post contrast pelviabdominal CT, MRI or PET/CT 3-6 months later. The .sup.18FDG PET/CT scan was positive in 62 patients, and it was negative in 14 patients. Specificity, sensitivity, negative predictive value, as well as positive predictive value and diagnostic accuracy of integrated PET/CT, were found to be 92.3%, 96.3%, 96.1%, 85.7% and 98.4%, respectively. .sup.18F-FDG PET/CT is a valuable imaging tool for assessment of ovarian cancer patients presented with elevated CA-125 tumor marker serum level.
Publisher
Springer
Subject
